Calmolan® retard contains the active substance pramipexole.
Calmolan® retard belongs to the group of dopamine agonists that stimulate the dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help control body movements.
Calmolan® retard Is indicated in adults for the symptomatic treatment of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. throughout the course of the disease up to the advanced stage, when the effect of levodopa decreases or becomes irregular and fluctuations in therapeutic effect occur (so-called end-of-dose or on-off phenomena).
| Strength | Pack size |
| 0,26 mg | 10 |
| 0,52 mg | 10, 30 |
| 1,05 mg | 10, 30 |
| 2,1 mg | 10, 30 |
| 3,15 mg | 30 |
We ask for your understanding that due to the Austrian Medicines Act, certain further information is only accessible to medical professionals.
Login
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Turnstile. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information